Blankart, Carl Rudolf Berchtold; Milstein, Ricarda; Rybczynski, Meike; Schüler, Helke; von Kodolitsch, Yskert (2016). Economic and care considerations of Marfan syndrome. Expert review of pharmacoeconomics & outcomes research, 16(5), pp. 591-598. Taylor & Francis 10.1080/14737167.2016.1240619
Full text not available from this repository.INTRODUCTION
Marfan syndrome is a rare multisystem disease of the connective tissue, which affects multiple organ systems. advances in healthcare have doubled the life-expectancy of patients over the past three decades. to date, there is no comprehensive review that consolidates economic considerations and care for marfan patients. Areas covered: Present research suggests that there may be a link between treatment pattern, disease progression and economic costs of Marfan syndrome. It indicates that an early detection of the disease and preventive interventions achieve a dual aim. From a patient perspective, it may reduce the amount of emergency surgery or intervention, and inpatient stays. In addition, it slows disease progression, lowers lifestyle restrictions, reduces psychological stress, and improves health-related quality of life. Expert commentary: Early detection and preventive measures are likely to achieve a dual aim by simultaneously containing costs and reducing the number and length of inpatient stays.
Item Type: |
Journal Article (Original Article) |
---|---|
Division/Institute: |
11 Centers of Competence > KPM Center for Public Management |
UniBE Contributor: |
Blankart, Rudolf |
Subjects: |
300 Social sciences, sociology & anthropology > 350 Public administration & military science 300 Social sciences, sociology & anthropology > 330 Economics |
ISSN: |
1744-8379 |
Publisher: |
Taylor & Francis |
Language: |
English |
Submitter: |
Carl Rudolf Berchtold Blankart |
Date Deposited: |
05 Apr 2018 17:26 |
Last Modified: |
05 Dec 2022 15:11 |
Publisher DOI: |
10.1080/14737167.2016.1240619 |
PubMed ID: |
27662508 |
Uncontrolled Keywords: |
FBN1 Loeys-Dietz syndrome Marfan syndrome TGFBR2 costs decision-making economy gene healthcare surgery |
URI: |
https://boris.unibe.ch/id/eprint/111994 |